What You Should Know:
– Lunit, a provider of AI for cancer diagnostics, and Agilent Technologies Inc., a global leader in life sciences, have announced a nonexclusive collaboration to develop AI-based companion diagnostic solutions.
– The strategic partnership will combine Lunit’s AI technology with Agilent’s expertise in tissue-based companion diagnostics. The goal is to create advanced solutions that meet the demands of novel and complex biomarker assays in drug development.
Accelerating Precision Oncology with AI
The collaboration will initially focus on co-developing AI-powered assays for use in research and clinical trials. This will enhance the accuracy of diagnosis and the measurement of therapeutic efficacy. The joint solutions will support pharmaceutical companies in companion diagnostic (CDx) product development, which will improve the precision of biomarker testing. Ultimately, this will benefit patients by providing more tailored treatment options.
“Biomarker testing is at the heart of precision oncology, but today it is still largely dependent on manual interpretation,” said Brandon Suh, CEO of Lunit. “By combining Agilent’s global leadership in tissue-based diagnostics with Lunit’s proven AI algorithms, we can help pharma partners bring biomarker-driven therapies to market faster and with greater confidence – ultimately ensuring patients receive the right treatment at the right time.”
